PL3140303T3 - Związki imidazo[4,5-c]chinolin-2-onu i ich zastosowanie w leczeniu nowotworów - Google Patents

Związki imidazo[4,5-c]chinolin-2-onu i ich zastosowanie w leczeniu nowotworów

Info

Publication number
PL3140303T3
PL3140303T3 PL15724351T PL15724351T PL3140303T3 PL 3140303 T3 PL3140303 T3 PL 3140303T3 PL 15724351 T PL15724351 T PL 15724351T PL 15724351 T PL15724351 T PL 15724351T PL 3140303 T3 PL3140303 T3 PL 3140303T3
Authority
PL
Poland
Prior art keywords
quinolin
imidazo
compounds
treating cancer
cancer
Prior art date
Application number
PL15724351T
Other languages
English (en)
Inventor
Bernard Christophe Barlaam
Kurt Gordon Pike
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PL3140303T3 publication Critical patent/PL3140303T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/502Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL15724351T 2014-05-08 2015-05-05 Związki imidazo[4,5-c]chinolin-2-onu i ich zastosowanie w leczeniu nowotworów PL3140303T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461990232P 2014-05-08 2014-05-08
EP15724351.0A EP3140303B1 (en) 2014-05-08 2015-05-05 Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
PCT/GB2015/051312 WO2015170081A1 (en) 2014-05-08 2015-05-05 Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer

Publications (1)

Publication Number Publication Date
PL3140303T3 true PL3140303T3 (pl) 2018-08-31

Family

ID=53264681

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15724351T PL3140303T3 (pl) 2014-05-08 2015-05-05 Związki imidazo[4,5-c]chinolin-2-onu i ich zastosowanie w leczeniu nowotworów

Country Status (39)

Country Link
US (4) US9428503B2 (pl)
EP (1) EP3140303B1 (pl)
JP (1) JP6505131B2 (pl)
KR (1) KR102013021B1 (pl)
CN (1) CN106255692B (pl)
AP (1) AP2016009532A0 (pl)
AR (1) AR100340A1 (pl)
AU (1) AU2015257456B2 (pl)
CA (1) CA2946459C (pl)
CL (1) CL2016002735A1 (pl)
CR (1) CR20160523A (pl)
CY (1) CY1120248T1 (pl)
DK (1) DK3140303T3 (pl)
DO (1) DOP2016000281A (pl)
EA (1) EA031674B1 (pl)
ES (1) ES2670416T3 (pl)
HR (1) HRP20180697T1 (pl)
HU (1) HUE037558T2 (pl)
IL (1) IL248397B (pl)
LT (1) LT3140303T (pl)
MA (1) MA39960A (pl)
MX (1) MX374401B (pl)
NI (1) NI201600166A (pl)
NO (1) NO2714752T3 (pl)
NZ (1) NZ726042A (pl)
PE (1) PE20170403A1 (pl)
PH (1) PH12016502168A1 (pl)
PL (1) PL3140303T3 (pl)
PT (1) PT3140303T (pl)
RS (1) RS57223B1 (pl)
SG (1) SG11201609164VA (pl)
SI (1) SI3140303T1 (pl)
SM (1) SMT201800259T1 (pl)
SV (1) SV2016005312A (pl)
TN (1) TN2016000458A1 (pl)
TR (1) TR201807101T4 (pl)
TW (1) TWI662034B (pl)
UY (1) UY36112A (pl)
WO (1) WO2015170081A1 (pl)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3277681B1 (de) * 2015-04-02 2019-05-08 Merck Patent GmbH Imidazolonylchinoline und deren verwendung als atm kinase inhibitoren
GB201516504D0 (en) 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
GB201519406D0 (en) * 2015-11-03 2015-12-16 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
GB201519568D0 (en) * 2015-11-05 2015-12-23 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
EP4071174A1 (en) * 2016-02-15 2022-10-12 AstraZeneca AB Methods comprising fixed intermittent dosing of cediranib
PE20181895A1 (es) * 2016-03-21 2018-12-11 Astrazeneca Ab Compuestos de cinnolin-4-amina y su uso en el tratamiento del cancer
WO2017174446A1 (en) 2016-04-07 2017-10-12 Astrazeneca Ab N,n-dimethyl-3-[[5-(3-methyl-2-oxo-1-tetrahydropyran-4-yl-imidazo[4,5-c]quinolin-8-yl)-2-pyridyl]oxy]propan-1-amine oxide as atm (ataxia telangiectasia mutated) kinase modulator for treating cancer
GB201608227D0 (en) * 2016-05-11 2016-06-22 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
NZ755222A (en) 2016-12-20 2022-07-01 Astrazeneca Ab Amino-triazolopyridine compounds and their use in treating cancer
WO2018127195A1 (zh) * 2017-01-09 2018-07-12 上海瑛派药业有限公司 取代的稠合杂芳基化合物作为激酶抑制剂及其应用
CN106798741A (zh) * 2017-02-07 2017-06-06 宫英 一种治疗抑郁症的药物组合物
CN106692147A (zh) * 2017-02-07 2017-05-24 李明英 一种治疗男性不育的药物组合物
CN106822123A (zh) * 2017-02-09 2017-06-13 王艳苓 一种治疗心脑血管疾病的药物组合物
WO2018153365A1 (zh) * 2017-02-27 2018-08-30 上海瑛派药业有限公司 取代的稠合杂芳三环化合物作为激酶抑制剂及其应用
JOP20190209A1 (ar) * 2017-03-16 2019-09-12 Astrazeneca Ab مركبات إيميدازو [ 4، 5-c ] كينولين-2-أون ديوترومية واستخدامها في علاج السرطان
CN111344293A (zh) 2017-09-20 2020-06-26 阿斯利康(瑞典)有限公司 1,3-二氢咪唑并[4,5-c]噌啉-2-酮化合物及其在治疗癌症中的用途
CN110386932A (zh) * 2018-04-20 2019-10-29 艾科思莱德制药公司 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂
WO2019201283A1 (en) * 2018-04-20 2019-10-24 Xrad Therapeutics, Inc. Dual atm and dna-pk inhibitors for use in anti-tumor therapy
ES3001444T3 (en) * 2018-09-14 2025-03-05 Suzhou Zanrong Pharma Ltd 1-isopropyl-3-methyl-8- (pyridin-3-yl) -1, 3-dihydro-2h-imidazo [4, 5-c] cinnolin-2-one as selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof
US20210369705A1 (en) * 2018-10-15 2021-12-02 Merck Patent Gmbh Combination therapy utilizing dna alkylating agents and atr inhibitors
CN113508118B (zh) * 2019-03-05 2024-07-19 阿斯利康(瑞典)有限公司 用作抗癌剂的稠合三环化合物
TW202102497A (zh) * 2019-03-29 2021-01-16 瑞典商阿斯特捷利康公司 化合物及它們在治療癌症中之用途
CN111909147B (zh) * 2019-05-10 2021-07-20 山东轩竹医药科技有限公司 Dna-pk抑制剂
US20220259211A1 (en) * 2019-07-10 2022-08-18 Impact Therapeutics (Shanghai), Inc Substituted pyrazoloquinazolinone compounds and application thereof
CA3149883A1 (en) * 2019-09-12 2021-03-18 Sui Xiong Cai Substituted imidazoquinoxaline compounds and uses thereof
CN115003672A (zh) * 2020-01-09 2022-09-02 南京明德新药研发有限公司 喹啉并咪唑类化合物及其应用
WO2021146127A1 (en) * 2020-01-13 2021-07-22 Zhanggui Wu Use of n2-quincline or isoquinoline substituted purine derivatives in cancer treatment
JP2023539715A (ja) * 2020-06-24 2023-09-19 アストラゼネカ ユーケー リミテッド 抗体-薬物コンジュゲートとatm阻害剤との組合わせ
EP3992191A1 (en) 2020-11-03 2022-05-04 Deutsches Krebsforschungszentrum Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors
CN117015534A (zh) * 2021-02-03 2023-11-07 艾科思莱德制药公司 用于癌症疗法的双重atm和dna-pk抑制剂以及免疫治疗剂的组合
AU2021433713A1 (en) * 2021-03-17 2023-09-28 Suzhou Zanrong Pharma Limited Selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof
MX2024009184A (es) * 2022-01-26 2024-07-30 Chia Tai Tianqing Pharmaceutical Group Co Ltd Compuesto que contiene grupo hidrazino.
CN121038817A (zh) 2023-04-10 2025-11-28 第一三共株式会社 抗-b7-h3抗体-药物缀合物和atr抑制剂或atm抑制剂的组合

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211649D0 (en) * 2002-05-21 2002-07-03 Novartis Ag Organic compounds
BRPI0416801A (pt) 2003-11-21 2007-01-09 Novartis Ag derivados de 1h-imidazoquinolina como inibidores de proteìna sinase
GB0510390D0 (en) * 2005-05-20 2005-06-29 Novartis Ag Organic compounds
PE20090717A1 (es) * 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
PE20110570A1 (es) 2008-07-01 2011-08-26 Genentech Inc Heterociclos biciclicos sustituidos
EP2356120B1 (en) * 2008-09-30 2016-10-12 Pfizer Inc. Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions
TW201041888A (en) * 2009-05-06 2010-12-01 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
WO2010139731A1 (en) 2009-06-04 2010-12-09 Novartis Ag 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES
JP2012528829A (ja) * 2009-06-04 2012-11-15 ノバルティス アーゲー 1H−イミダゾ[4,5−c]キノリノン化合物
RU2557658C2 (ru) * 2009-09-28 2015-07-27 Ф.Хоффманн-Ля Рош Аг Бензоксепиновые ингибиторы pi3 и способы применения
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
CN102199152A (zh) 2010-03-25 2011-09-28 高大新 杂环咪唑类磷脂激酶抑制剂
CN102372711B (zh) * 2010-08-18 2014-09-17 山东轩竹医药科技有限公司 咪唑并喹啉类PI3K和mTOR双重抑制剂
WO2012026233A1 (ja) 2010-08-26 2012-03-01 日立建機株式会社 建設機械
DE102010035744A1 (de) 2010-08-28 2012-03-01 Merck Patent Gmbh Imidazolonylchinoline
CN102399218A (zh) 2010-09-16 2012-04-04 和记黄埔医药(上海)有限公司 一类并合三杂环及其作为pi3k抑制剂的用途
BR112013013837A2 (pt) 2010-12-06 2016-09-13 Piramal Entpr Ltd derivados de substituição de imidazoquinolina
EP2694678A2 (en) 2011-04-04 2014-02-12 Netherland Cancer Institute Methods and compositions for predicting resistance to anticancer treatment
JP6042060B2 (ja) * 2011-09-26 2016-12-14 サノフイ ピラゾロキノリノン誘導体、その調製および治療上の使用

Also Published As

Publication number Publication date
PH12016502168B1 (en) 2016-12-19
RS57223B1 (sr) 2018-07-31
TR201807101T4 (tr) 2018-06-21
EP3140303B1 (en) 2018-03-28
EA031674B1 (ru) 2019-02-28
MA39960A (fr) 2018-03-28
US20150336952A1 (en) 2015-11-26
MX2016014639A (es) 2017-03-06
US20190185468A1 (en) 2019-06-20
NZ726042A (en) 2018-08-31
UY36112A (es) 2015-10-30
JP6505131B2 (ja) 2019-04-24
EP3140303A1 (en) 2017-03-15
AR100340A1 (es) 2016-09-28
TW201625609A (zh) 2016-07-16
SV2016005312A (es) 2017-03-16
AU2015257456B2 (en) 2018-02-15
US10189834B2 (en) 2019-01-29
SMT201800259T1 (it) 2018-07-17
EA201692095A1 (ru) 2017-08-31
PE20170403A1 (es) 2017-05-07
CA2946459C (en) 2022-07-12
IL248397B (en) 2019-02-28
SI3140303T1 (en) 2018-06-29
AU2015257456A1 (en) 2016-11-24
BR112016025153A2 (pt) 2017-08-15
US9822111B2 (en) 2017-11-21
US9428503B2 (en) 2016-08-30
CL2016002735A1 (es) 2017-02-10
CY1120248T1 (el) 2019-07-10
AP2016009532A0 (en) 2016-11-30
CA2946459A1 (en) 2015-11-12
LT3140303T (lt) 2018-05-25
KR102013021B1 (ko) 2019-08-21
BR112016025153A8 (pt) 2021-07-20
NI201600166A (es) 2017-03-13
PT3140303T (pt) 2018-05-25
SG11201609164VA (en) 2016-12-29
MX374401B (es) 2025-03-06
WO2015170081A1 (en) 2015-11-12
CN106255692B (zh) 2019-02-26
JP2017514877A (ja) 2017-06-08
US20180134699A1 (en) 2018-05-17
PH12016502168A1 (en) 2016-12-19
CN106255692A (zh) 2016-12-21
NO2714752T3 (pl) 2018-04-21
KR20160147054A (ko) 2016-12-21
DOP2016000281A (es) 2016-12-15
HRP20180697T1 (hr) 2018-06-01
US20160368920A1 (en) 2016-12-22
CR20160523A (es) 2017-04-27
TWI662034B (zh) 2019-06-11
DK3140303T3 (en) 2018-06-06
TN2016000458A1 (en) 2018-04-04
HUE037558T2 (hu) 2018-09-28
ES2670416T3 (es) 2018-05-30

Similar Documents

Publication Publication Date Title
IL248397B (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
IL258818A (en) Imidazo[4,5-c]quinolin-2-ion compounds and their use in cancer treatment
IL258828A (en) Imidazo[4,5-c]quinolin-2-ion compounds and their use in cancer therapy
ZA201904695B (en) Amino-triazolopyridine compounds and their use in treating cancer
GB201516504D0 (en) Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
GB201608227D0 (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
PL3007694T3 (pl) Pochodne pirazolopirydynowe do zastosowania w leczeniu nowotworu pęcherza moczowego
IL266198A (en) Liposomal formulation for use in cancer treatment
IL251903B (en) Epilimod for use in the treatment of colon cancer
IL269272A (en) Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
IL262656A (en) Nanoliposomal irinotecan for use in the treatment of small cell lung cancer
GB201604182D0 (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
IL250104A0 (en) [1,2,4]triazolo[3-b,4]pyridines for the treatment of proliferative diseases
IL261648A (en) Cinnolin-4-amine compounds and their use in treating cancer
IL259358A (en) Bis-pyridazine compounds and their use in treating cancer
HK40091842A (zh) 用於癌症治疗的单独fgfr2抑制剂或与免疫刺激剂的组合
HK1255487A1 (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
ZA201704727B (en) New imidazo[1,2-a]quinoxalines and derivates thereof for the treatment of cancer
HK40022419A (en) Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
HK1259160A1 (en) Bis-pyridazine compounds and their use in treating cancer
HK1260394A1 (en) Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
GB201510764D0 (en) bis-Pyridazine compounds and their use in treating cancer
GB201411111D0 (en) bis-Pyridazine compounds and their use in treating cancer
GB201516220D0 (en) Pyrrolo[2,3-d]pyrimidin-4-amine compounds and their use in treating cancer
GB201406986D0 (en) Bicyclic heterocycle compounds and their uses in therapy